Author: Salian, Vrishali S.; Wright, Jessica A.; Vedell, Peter T.; Nair, Sanjana; Li, Chenxu; Kandimalla, Mahathi; Tang, Xiaojia; Carmona Porquera, Eva M.; Kalari, Krishna R.; Kandimalla, Karunya K.
Title: COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies Cord-id: 63ynchqb Document date: 2021_1_19
ID: 63ynchqb
Snippet: [Image: see text] At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a global pandemic, was identified in the Chinese city of Wuhan. Although unique in its transmission and virulence, COVID-19 is similar to zoonotic diseases, including other SARS variants (e.g., SARS-CoV) and MERS, in exhibiting severe flu-like symptoms and acute respiratory distress. Even at the molecular level, many parallels have been identified between SARS and COVID-19 so much so that the
Document: [Image: see text] At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a global pandemic, was identified in the Chinese city of Wuhan. Although unique in its transmission and virulence, COVID-19 is similar to zoonotic diseases, including other SARS variants (e.g., SARS-CoV) and MERS, in exhibiting severe flu-like symptoms and acute respiratory distress. Even at the molecular level, many parallels have been identified between SARS and COVID-19 so much so that the COVID-19 virus has been named SARS-CoV-2. These similarities have provided several opportunities to treat COVID-19 patients using clinical approaches that were proven to be effective against SARS. Importantly, the identification of similarities in how SARS-CoV and SARS-CoV-2 access the host, replicate, and trigger life-threatening pathological conditions have revealed opportunities to repurpose drugs that were proven to be effective against SARS. In this article, we first provided an overview of COVID-19 etiology vis-Ã -vis other zoonotic diseases, particularly SARS and MERS. Then, we summarized the characteristics of droplets/aerosols emitted by COVID-19 patients and how they aid in the transmission of the virus among people. Moreover, we discussed the molecular mechanisms that enable SARS-CoV-2 to access the host and become more contagious than other betacoronaviruses such as SARS-CoV. Further, we outlined various approaches that are currently being employed to diagnose and symptomatically treat COVID-19 in the clinic. Finally, we reviewed various approaches and technologies employed to develop vaccines against COVID-19 and summarized the attempts to repurpose various classes of drugs and novel therapeutic approaches.
Search related documents:
Co phrase search for related documents- abdominal pain and accompany abdominal pain: 1, 2, 3
- abdominal pain and accompany abdominal pain diarrhea nausea: 1, 2
- abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
- abdominal pain and acute cardiac injury: 1, 2
- abdominal pain and acute inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abdominal pain and acute respiratory failure: 1, 2, 3, 4, 5, 6
- abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- abdominal pain and adenoviral vaccine: 1
- abdominal pain and adipose tissue: 1, 2, 3
- abdominal pain and administration route: 1
- abdominal pain and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and long survive: 1
- abdominal pain and long term efficacy: 1
- abdominal pain and low mortality: 1, 2
- abdominal pain and low respiratory tract: 1
- abdominal pain and lower respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- abdominal pain and lower respiratory tract: 1, 2, 3, 4, 5
- abdominal pain and lung function: 1, 2, 3, 4
- abdominal pain and lung tissue: 1, 2
Co phrase search for related documents, hyperlinks ordered by date